Technical Analysis for CDTX - Cidara Therapeutics, Inc.

Grade Last Price % Change Price Change
B 13.09 0.69% 0.09
CDTX closed up 0.69 percent on Friday, November 1, 2024, on 53 percent of normal volume. It was able to bounce off of its 200 day moving average, an important long-term support line.
3 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up

Date Alert Name Type % Chg
200 DMA Support Bullish 0.00%
Calm After Storm Range Contraction 0.00%
Earnings Movers Other 0.00%
Outside Day Range Expansion 0.00%
Wide Bands Range Expansion 0.00%
Crossed Above 200 DMA Bullish 0.69%
180 Bullish Setup Bullish Swing Setup 0.69%
Boomer Buy Setup Bullish Swing Setup 0.69%
Calm After Storm Range Contraction 0.69%
NR7 Range Contraction 0.69%

   Recent Intraday Alerts

Alert Time
60 Minute Opening Range Breakout about 22 hours ago
200 DMA Support about 23 hours ago
Boomer Buy Entry about 23 hours ago
Bullish 180 Entry about 23 hours ago
Rose Above Previous Day's High about 23 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Cidara Therapeutics, Inc. Description

Cidara Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel anti-infectives for the treatment of diseases. Its lead product candidate is CD101 IV, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of systemic Candida infections. The company also develops CD101 topical, a topical formulation of CD101 for the treatment of recurrent vulvovaginal candidiasis, a prevalent mucosal infection. In addition, it develops a proprietary immunotherapy technology platform, Cloudbreak, which is used to create compounds designed to direct a patient's immune cells to attack and eliminate pathogens that cause infectious disease. Cidara Therapeutics is developing its first Cloudbreak development candidate, C001, for the treatment of invasive aspergillosis; and evaluating additional opportunities to expand its Cloudbreak immunotherapy platform to other areas of infectious disease. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in June 2014. Cidara Therapeutics, Inc. was founded in 2012 and is based in San Diego, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Disease Immunotherapy Infectious Diseases Anti Infectives Vagina Candidiasis Immunotherapy Technology

Is CDTX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 24.4
52 Week Low 10.004
Average Volume 19,993
200-Day Moving Average 12.97
50-Day Moving Average 11.54
20-Day Moving Average 11.49
10-Day Moving Average 12.24
Average True Range 0.67
RSI (14) 66.67
ADX 36.61
+DI 31.76
-DI 5.65
Chandelier Exit (Long, 3 ATRs) 11.90
Chandelier Exit (Short, 3 ATRs) 12.16
Upper Bollinger Bands 13.46
Lower Bollinger Band 9.52
Percent B (%b) 0.9
BandWidth 34.29
MACD Line 0.48
MACD Signal Line 0.22
MACD Histogram 0.2597
Fundamentals Value
Market Cap 1.18 Billion
Num Shares 90.4 Million
EPS -0.39
Price-to-Earnings (P/E) Ratio -33.56
Price-to-Sales 1.12
Price-to-Book 8.19
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 13.79
Resistance 3 (R3) 13.73 13.43 13.68
Resistance 2 (R2) 13.43 13.25 13.46 13.64
Resistance 1 (R1) 13.26 13.14 13.34 13.32 13.60
Pivot Point 12.96 12.96 13.00 12.99 12.96
Support 1 (S1) 12.79 12.78 12.88 12.86 12.58
Support 2 (S2) 12.49 12.67 12.52 12.54
Support 3 (S3) 12.32 12.49 12.50
Support 4 (S4) 12.39